Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Other equities research analysts have also recently issued reports about the company. Lifesci Capital upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 27th. The Goldman Sachs Group raised their price objective on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 15th. Guggenheim increased their target price on Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Finally, Robert W. Baird lifted their price target on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Amylyx Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Check Out Our Latest Stock Analysis on AMLX

Amylyx Pharmaceuticals Price Performance

NASDAQ:AMLX opened at $12.02 on Friday. The company has a 50 day moving average price of $13.79 and a 200-day moving average price of $10.69. Amylyx Pharmaceuticals has a 1-year low of $2.60 and a 1-year high of $16.96. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -6.68 and a beta of -0.34.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. On average, sell-side analysts anticipate that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James M. Frates sold 10,558 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $14.65, for a total value of $154,674.70. Following the sale, the chief financial officer directly owned 280,430 shares of the company’s stock, valued at $4,108,299.50. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gina Mazzariello sold 8,828 shares of the stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $14.58, for a total value of $128,712.24. Following the completion of the transaction, the insider directly owned 148,141 shares of the company’s stock, valued at approximately $2,159,895.78. This represents a 5.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 97,913 shares of company stock valued at $1,413,918. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. California State Teachers Retirement System purchased a new position in shares of Amylyx Pharmaceuticals in the second quarter worth about $28,000. Ameritas Investment Partners Inc. acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at about $45,000. BNP Paribas Financial Markets raised its holdings in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after acquiring an additional 5,904 shares during the last quarter. Legal & General Group Plc purchased a new position in Amylyx Pharmaceuticals in the 2nd quarter worth approximately $47,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Amylyx Pharmaceuticals during the 3rd quarter worth approximately $48,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.

Featured Stories